$MIRA

Is Mira Pharmaceuticals Gaining or Losing Market Support? - Mira Pharmaceuticals (NASDAQ:MIRA)

Mira Pharmaceuticals's MIRA short percent of float has fallen 41.3% since its last report. The company recently reported that it has 574 thousand shares sold short, which is 4.59% of all regular shares that are available for trading.

Original reporting
Benzinga · Benzinga Insights
Published Apr 17, 2025, 5:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 17, 2025, 6:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Is Mira Pharmaceuticals Gaining or Losing Market Support? - Mira Pharmaceuticals (NASDAQ:MIRA) — source image
Decision brief

The 30-second read

$MIRANeutralLow
01

Why it matters

The recent decline in short interest suggests reduced bearish pressure, potentially supporting a price rally, but limited by overall low relevance and trading volume.

02

Market read

The news has limited immediate trading impact due to low relevance score but may influence short-term sentiment.

03

What to watch

Potential upcoming company news, earnings reports, or sector-wide developments could override current sentiment signals.

Timing: short-term

Background

Mira Pharmaceuticals has experienced fluctuating short interest levels, which can influence market perception and stock price volatility.

Company-level read

Ticker impact

$MIRANeutralMedium confidence
Context

The news indicates a significant decrease in short interest for Mira Pharmaceuticals, which may suggest a reduction in bearish sentiment.

Expected impact

Moderate upward price movement expected if short covering continues, but limited by overall low relevance.

Evidence & confidence

The reduction in short interest suggests decreased bearish sentiment, which could support a price increase. However, the overall low relevance score (0.203) and limited trading volume data constrain the strength of this signal.

Market effects

Possible positive sentiment shift within the Life Sciences sector due to reduced short interest in a biotech firm.

Limited regional impact; primarily relevant to US-based investors.

Minimal global market influence given the company's size and low relevance score.

Counterpoint

The decrease in short interest may be a temporary correction rather than a definitive bullish signal; institutional investors might be repositioning for other reasons.

Key entities

  • Mira Pharmaceuticals

    A biotech firm listed on NASDAQ involved in pharmaceutical development.

Related articles

$MIRAMed

MIRA Flat at Open

MIRA Pharmaceuticals (NASDAQ:MIRA) shares were flat at the open. The company said new preclinical pharmacology data for its cannabinoid analog Mira-55 in chronic inflammatory pain showed a THC-like receptor profile but different effects, including an anxiolytic effect not seen with THC. MIRA also referenced March 2026 animal data versus rimonabant.

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.